Terms: = Prostate cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1
329 results:
1. Loss of Y in regulatory T lymphocytes in the tumor micro-environment of primary colorectal cancers and liver metastases.
Wójcik M; Juhas U; Mohammadi E; Mattisson J; Drężek-Chyła K; Rychlicka-Buniowska E; Bruhn-Olszewska B; Davies H; Chojnowska K; Olszewski P; Bieńkowski M; Jankowski M; Rostkowska O; Hellmann A; Pęksa R; Kowalski J; Zdrenka M; Kobiela J; Zegarski W; Biernat W; Szylberg Ł; Remiszewski P; Mieczkowski J; Filipowicz N; Dumanski JP
Sci Rep; 2024 Apr; 14(1):9458. PubMed ID: 38658633
[TBL] [Abstract] [Full Text] [Related]
2. Understanding and overcoming resistance to immunotherapy in genitourinary cancers.
Evans ST; Jani Y; Jansen CS; Yildirim A; Kalemoglu E; Bilen MA
Cancer Biol Ther; 2024 Dec; 25(1):2342599. PubMed ID: 38629578
[TBL] [Abstract] [Full Text] [Related]
3. Targeted Ultrasound Nanobubbles Therapy for prostate cancer via Immuno-Sonodynamic Effect.
Huang X; Chen Y; Zhong F; Gui B; Hu Y; Guo Y; Deng Q; Zhou Q
Int J Nanomedicine; 2024; 19():2793-2806. PubMed ID: 38525011
[TBL] [Abstract] [Full Text] [Related]
4. Tyrosine phosphatase
Chen X; Keller SJ; Hafner P; Alrawashdeh AY; Avery TY; Norona J; Zhou J; Ruess DA
Front Immunol; 2024; 15():1340726. PubMed ID: 38504984
[TBL] [Abstract] [Full Text] [Related]
5. Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06).
Kim JW; Lee HJ; Lee JY; Park SR; Kim YJ; Hwang IG; Kyun Bae W; Byun JH; Kim JS; Kang EJ; Lee J; Shin SJ; Chang WJ; Kim EO; Sa JK; Park KH
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38485184
[TBL] [Abstract] [Full Text] [Related]
6. Network pharmacology and experimental evaluation strategies to decipher the underlying pharmacological mechanism of Traditional Chinese Medicine CFF-1 against prostate cancer.
Wei Y; Zhu M; Chen Y; Ji Q; Wang J; Shen L; Yang X; Hu H; Zhou X; Zhu Q
Aging (Albany NY); 2024 Mar; 16(6):5387-5411. PubMed ID: 38484140
[TBL] [Abstract] [Full Text] [Related]
7. A phase 1 trial of human telomerase reverse transcriptase (hTERT) vaccination combined with therapeutic strategies to control immune-suppressor mechanisms.
Zareian N; Eremin O; Pandha H; Baird R; Kwatra V; Funingana G; Verma C; Choy D; Hargreaves S; Moghimi P; Shepherd A; Lobo DN; Eremin J; Farzaneh F; Kordasti S; Spicer J
Exp Biol Med (Maywood); 2024; 249():10021. PubMed ID: 38463391
[TBL] [Abstract] [Full Text] [Related]
8. Pembrolizumab for metastatic castration-resistant prostate cancer: trials and tribulations.
Tsai AK; Kagalwalla S; Langer J; Le-Kumar T; Le-Kumar V; Antonarakis ES
Expert Opin Biol Ther; 2024; 24(1-2):51-62. PubMed ID: 38284349
[TBL] [Abstract] [Full Text] [Related]
9. Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer.
Galsky MD; Guan X; Rishipathak D; Rapaport AS; Shehata HM; Banchereau R; Yuen K; Varfolomeev E; Hu R; Han CJ; Li H; Liang Y; Vucic D; Wang L; Zhu J; Yu H; Herbst RH; Hajaj E; Kiner E; Bamias A; De Santis M; Davis ID; Arranz JÁ; Kikuchi E; Bernhard S; Williams P; Lee C; Mellman I; Sanjabi S; Johnston R; Black PC; Grande E; Mariathasan S
Cell Rep Med; 2024 Feb; 5(2):101393. PubMed ID: 38280376
[TBL] [Abstract] [Full Text] [Related]
10. The radiopharmaceutical radium-223 has immunomodulatory effects in patients and facilitates anti-programmed death receptor-1 therapy in murine models of bone metastatic prostate cancer.
Saylor PJ; Kozin SV; Matsui A; Goldberg SI; Aoki S; Shigeta K; Mamessier E; Smith MR; Michaelson MD; Lee RJ; Duda DG
Radiother Oncol; 2024 Mar; 192():110091. PubMed ID: 38224917
[TBL] [Abstract] [Full Text] [Related]
11. Comparative Evaluation of STEAP1 Targeting Chimeric Antigen Receptors with Different Costimulatory Domains and Spacers.
Jin Y; Dunn C; Persiconi I; Sike A; Skorstad G; Beck C; Kyte JA
Int J Mol Sci; 2024 Jan; 25(1):. PubMed ID: 38203757
[TBL] [Abstract] [Full Text] [Related]
12. Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial.
Markowski MC; Taplin ME; Aggarwal R; Sena LA; Wang H; Qi H; Lalji A; Sinibaldi V; Carducci MA; Paller CJ; Marshall CH; Eisenberger MA; Sanin DE; Yegnasubramanian S; Gomes-Alexandre C; Ozbek B; Jones T; De Marzo AM; Denmeade SR; Antonarakis ES
Nat Commun; 2024 Jan; 15(1):14. PubMed ID: 38167882
[TBL] [Abstract] [Full Text] [Related]
13. Moving toward improved immune checkpoint immunotherapy for advanced prostate cancer.
De Velasco MA; Kura Y; Fujita K; Uemura H
Int J Urol; 2024 Apr; 31(4):307-324. PubMed ID: 38167824
[TBL] [Abstract] [Full Text] [Related]
14. Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer.
McNeel DG; Emamekhoo H; Eickhoff JC; Kyriakopoulos CE; Wargowski E; Tonelli TP; Johnson LE; Liu G
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38101860
[TBL] [Abstract] [Full Text] [Related]
15. Interleukin-30 subverts prostate cancer-endothelium crosstalk by fostering angiogenesis and activating immunoregulatory and oncogenic signaling pathways.
Ciummo SL; Sorrentino C; Fieni C; Di Carlo E
J Exp Clin Cancer Res; 2023 Dec; 42(1):336. PubMed ID: 38087324
[TBL] [Abstract] [Full Text] [Related]
16. Efficacy and safety of immune checkpoint inhibitors for patients with prostate cancer: a systematic review and meta-analysis.
Noori M; Azizi S; Mahjoubfar A; Abbasi Varaki F; Fayyaz F; Mousavian AH; Bashash D; Kardoust Parizi M; Kasaeian A
Front Immunol; 2023; 14():1181051. PubMed ID: 38022569
[TBL] [Abstract] [Full Text] [Related]
17. LRP5 competes for SPOP binding to enhance tumorigenesis mediated by Daxx and PD-L1 in prostate cancer.
Gan S; Qu F; Zhang X; Pan X; Xu D; Cui X; Hou J
Exp Cell Res; 2024 Jan; 434(1):113857. PubMed ID: 38008278
[TBL] [Abstract] [Full Text] [Related]
18. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
19. Efficacy and Safety of Programmed Death-1 (pd-1)/Programmed Death-Ligand 1 (PD-L1) Checkpoint Inhibitors in Patients With Metastatic Castration-resistant prostate cancer: A Systematic Review and Meta-analysis.
Hong X; Zhang Y; Chi Z; Xu Q; Lin W; Huang Y; Lin T; Zhang Y
Clin Oncol (R Coll Radiol); 2024 Jan; 36(1):e20-e30. PubMed ID: 37993317
[TBL] [Abstract] [Full Text] [Related]
20. Anti-pd-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer.
Hawley JE; Obradovic AZ; Dallos MC; Lim EA; Runcie K; Ager CR; McKiernan J; Anderson CB; Decastro GJ; Weintraub J; Virk R; Lowy I; Hu J; Chaimowitz MG; Guo XV; Zhang Y; Haffner MC; Worley J; Stein MN; Califano A; Drake CG
Cancer Cell; 2023 Nov; 41(11):1972-1988.e5. PubMed ID: 37922910
[TBL] [Abstract] [Full Text] [Related]
[Next]
